Moderate to Severe Glabellar Lines

6 drugs in development·3 companies·3 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
dysport	NEXIEN BIOPHARMA, INC. (NXEN)
jeuveau	Evolus, Inc. (EOLS)

Phase 2(2)

Drug	Company
Vehicle Control	Revance Therapeutics, Inc. (RVNC)
YY003	Revance Therapeutics, Inc. (RVNC)

Phase 1(1)

Drug	Company
JHM03	Revance Therapeutics, Inc. (RVNC)

Phase 4(1)

Drug	Company
Rcombinant botulinum toxin type A for injection（Eveotox)	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 6 drugs in development for Moderate to Severe Glabellar Lines across 3 companies.

There are 3 clinical trials targeting Moderate to Severe Glabellar Lines tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.